Skip to main content
SpringerLink
Log in

Vorstufen kutaner Plattenepithelkarzinome

Diagnostik und Therapie aktinischer Keratosen*

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© Julia Fromme

2

© Julia Fromme

Literatur

  1. Chetty P et al. Primary care review of actinic keratosis and its therapeutic options: a global perspective. Dermatol Ther (Heidelb). 2015;5(1):19-35

  2. Schaefer I et al. Prevalence and risk factors of actinic keratoses in Germany- analysis of multisource data. J Eur Acad Dermatol Venereol. 2014;28(3):309-13

  3. Boone MA et al. A new algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma based on in vivo analysis of optical properties by high-definition optical coherence tomography. J Eur Acad Dermatol Venereol. 2016;30(10):1714-25

  4. Sterry W, Stockfleth E. Maligne epitheliale Tumoren. In: Plewig G, Landthaler M, Burgdorf W et al. (Hrsg). Braun-Falco's Dermatologie, Venerologie und Allergologie. 2015. Springer, Berlin: 1645-9

  5. Cramer P, Stockfleth E. Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs. 2020;25(1):49-58

  6. Olsen EA et al. (1991) A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol. 1991;24(5 Pt 1):738-43

  7. Schmitz L et al. Actinic keratosis: correlation between clinical and histological classification systems. J Eur Acad Dermatol Venereol. 2016;30(8):1303-7

  8. Peris K et al. Dermatoskopische Merkmale der aktinischen Keratose. JDDG-J Ger Soc Dermatol. 2007;5(11):970-6

  9. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut, Langversion 1.1, 2020, AWMF Registernummer: 032/022OL; www.leitlinienprogramm-onkologie.de/leitlinien/aktinische-keratose-und-plattenepithelkarzinom-der-haut, abgerufen am 18. März 2021

  10. Casari A et al. Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. Biomedicines. 2018;6(1):8

  11. Schmitz L et al. Actinic keratoses show variable histological basal growth patterns - a proposed classification adjustment. J Eur Acad Dermatol Venereol. 2018;32(5):745-51

  12. Marks R et al. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1(8589):795-7

  13. Quaedvlieg PJ et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol. 2006;16(4):335-9

  14. Werner RN et al. The natural history of actinic keratosis: a systematic review. Br J Dermatol. 2013;169(3):502-18

  15. Fernández-Figueras MT et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29(5):991-7

  16. Heppt MV et al. S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. J Dtsch Dermatol Ges. 2020;18(3):275-94

  17. Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. 2014;9(6):e96829

  18. Dirschka T et al. Real world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J Dermatolog Treat. 2017;28(5):431-42

  19. Maltusch A et al. Modes of action of diclofenac 3 %/hyaluronic acid 2.5 % in the treatment of actinic keratosis. J Dtsch Dermatol Ges. 2011;9(12):1011-7

  20. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1 Pt 2):S6-S11

  21. Swanson N et al. Imiquimod 2.5 % and 3.75 % for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582-90

  22. Longley DB et al. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-8

  23. Allison RR, Moghissi K. Photodynamic Therapy (PDT): PDT Mechanisms. Clin Endosc. 2013;46(1):24-9

  24. Wiegell SR et al. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single-blinded study. Br J Dermatol. 2008;158(4):740-6

  25. Ulrich C et al. Cutaneous precancers in organ transplant recipients: an old enemy in a new surrounding. Br J Dermatol. 2003;149 Suppl 66:40-2

  26. Togsverd-Bo K et al. Combination of ablative fractional laser and daylight-mediated photo-dynamic therapy for actinic keratosis in organ transplant recipients - a randomized controlled trial. Br J Dermatol. 2015;172(2):467-74

  27. Leiter U et al. Kutanes Plattenepithelkarzinom. Hautarzt. 2016;67(11):857-66

  28. Krediet J et al. Sentinel lymph node biopsy and risk factors for predicting metastasis in cutaneous squamous cell carcinoma. Br J Dermatol. 2015;172(4):1029-36

  29. Stratigos AJ et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83-102

  30. Jambusaria-Pahlajani A et al. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35(4):574-85

  31. Amoils M et al. Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head Neck. 2017;39(5):881-5

  32. Wang JT et al. Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: Improved survival with the addition of adjuvant radiotherapy. Head Neck. 2012;34(11):1524-8

  33. Patel R, Chang ALS. Immune checkpoint inhibitors for treating advanced cutaneous squamous cell carcinoma. Am J Clin Dermatol. 2019;20(4):477-82

  34. Tongdee E et al. Advanced squamous cell carcinoma: what's new? Curr Derm Rep. 2019;8(3):117-21

  35. Ribero S et al. Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence? Curr Opin Oncol. 2017;29(2):129-35

  36. Migden MR et al. PD-1-Blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341-51

  37. Rischin D et al. Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. J Clin Oncol. 2020;38(15_suppl): 10018-10018

Download references

Author information

Authors and Affiliations

  1. Klinik für Dermatologie und Venerologie, Universitätsklinik Köln, Köln, Deutschland

    Julia Fromme &  Cornelia Mauch

Authors
  1. Julia Fromme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelia Mauch
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autorinnen erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen haben leiten lassen. Die Autorinnen legen folgende potenzielle Interessenkonflikte offen: J. E. Fromme: keine; C. Mauch: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fromme, J., Mauch, C. Diagnostik und Therapie aktinischer Keratosen*. InFo Hämatol Onkol 24, 41–51 (2021). https://doi.org/10.1007/s15004-021-8624-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-021-8624-8

Search

Navigation